Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer ...
A 2026 University of Münster study found that immature granulocyte count in a routine blood test predicts 30-day heart attack ...